GYRE (Gyre Therapeutics) Change In Other Working Capital : $-0.8 Mil (TTM As of Mar. 2025)

View and export this data going back to 2023. Start your Free Trial

What is Gyre Therapeutics Change In Other Working Capital?

Gyre Therapeutics's Change In Other Working Capital for the quarter that ended in Mar. 2025 was $0.0 Mil. It means Gyre Therapeutics's Other Working Capital increased by $0.0 Mil from Dec. 2024 to Mar. 2025 .

Gyre Therapeutics's Change In Other Working Capital for the fiscal year that ended in Dec. 2024 was $-0.8 Mil. It means Gyre Therapeutics's Other Working Capital declined by $0.8 Mil from Dec. 2023 to Dec. 2024 .

Gyre Therapeutics Change In Other Working Capital Historical Data

The historical data trend for Gyre Therapeutics's Change In Other Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gyre Therapeutics Change In Other Working Capital Chart

Gyre Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Change In Other Working Capital

-0.16

-0.43

-0.57

-0.79

Gyre Therapeutics Quarterly Data
	Dec21	Mar22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Other Working Capital	Get a 7-Day Free Trial							-	1.61	-0.19	-2.21	0.03

Gyre Therapeutics Change In Other Working Capital Calculation

Change In Other Working Capital is any increase or decrease between periods of other working capital that are not otherwise classified.

Change In Other Working Capital for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.8 Mil.

Gyre Therapeutics Change In Other Working Capital Related Terms

Thank you for viewing the detailed overview of Gyre Therapeutics's Change In Other Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Gyre Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » Change In Other Working Capital

Comparable Companies

Traded in Other Exchanges

L9S:Germany

Address

12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130

Website

https://www.gyretx.com

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.